Literature DB >> 15578104

Using modified antigenic sequences to develop cancer vaccines: are we losing the focus?

Danila Valmori1, Maha Ayyoub.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15578104      PMCID： PMC529422          DOI： 10.1371/journal.pmed.0010026

Source DB:  PubMed          Journal:  PLoS Med        ISSN： 1549-1277            Impact factor:   11.069


× No keyword cloud information.
  12 in total

1.  Cytotoxic T cells recognize fragments of the influenza nucleoprotein.

Authors:  A R Townsend; F M Gotch; J Davey
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

2.  Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.

Authors:  Valérie Dutoit; Robert N Taub; Kyriakos P Papadopoulos; Susan Talbot; Mary-Louise Keohan; Michelle Brehm; Sacha Gnjatic; Paul E Harris; Brygida Bisikirska; Philippe Guillaume; Jean-Charles Cerottini; Charles S Hesdorffer; Lloyd J Old; Danila Valmori
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.

Authors:  D Valmori; J F Fonteneau; C M Lizana; N Gervois; D Liénard; D Rimoldi; V Jongeneel; F Jotereau; J C Cerottini; P Romero
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

Review 4.  Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing.

Authors:  S Radoja; A B Frey
Journal:  Mol Med       Date:  2000-06       Impact factor: 6.354

Review 5.  Cancer vaccines based on dendritic cells loaded with tumor-associated antigens.

Authors:  N Burdin; P Moingeon
Journal:  Cell Biol Toxicol       Date:  2001       Impact factor: 6.691

6.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

Authors:  M R Parkhurst; M L Salgaller; S Southwood; P F Robbins; A Sette; S A Rosenberg; Y Kawakami
Journal:  J Immunol       Date:  1996-09-15       Impact factor: 5.422

7.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

8.  Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.

Authors:  M L Salgaller; F M Marincola; J N Cormier; S A Rosenberg
Journal:  Cancer Res       Date:  1996-10-15       Impact factor: 12.701

9.  Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.

Authors:  Zhiya Yu; Marc R Theoret; Christopher E Touloukian; Deborah R Surman; Scott C Garman; Lionel Feigenbaum; Tiffany K Baxter; Brian M Baker; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Diversity and recognition efficiency of T cell responses to cancer.

Authors:  Tor B Stuge; Susan P Holmes; Sahdev Saharan; Andrea Tuettenberg; Mario Roederer; Jeffrey S Weber; Peter P Lee
Journal:  PLoS Med       Date:  2004-11-30       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.